| Reference | Treatment | Number of patients | OS (months) |
| Karapetis et al. 2008 [21] wild-type K-ras | Cetuximab | 117 | 9.5 |
| Karapetis et al. 2008 [21] mutant K-ras | Cetuximab | 81 | 4.8 |
| Amado et al. 2008 [22] wild-type K-ras | Panitumumab | 124 | 8.1 |
| Amado et al. 2008 [22] mutant K-ras | Panitumumab | 84 | 4.9 |
| Grothey et al. 2013 [23] | Regorafenib | 500 | 6.4 |
| Burzynski et al. 2014 | PB + a targeted combination | 15 | 14.7 |